Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis

Cecchettin, M; Bellometti, Simona; Cremonesi, G; Solimeno, Luigi Piero; Torri, G

doi:10.1016/0753-3322(96)82691-6

Cited by 12 publications

(38 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ipriflavone effects on biochemieal markers of bone tumover are somewhat controversial. In an animal study, ipriflavone treatment was not associated with significant changes in serum alkaline phosphatase [16], and a clinical study reported a significant reduction of bone metabolie markers (serum osteocalcin, alkaline phosphatase) [17]. Although the changes were not statistically significant our study showed increased levels of bone metabolie markers after 1 year of treatment.…”

Section: Discussioncontrasting

confidence: 36%

See 1 more Smart Citation

Ipriflavone for the treatment of osteoporosis

1997

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 36%

“…Agnusdei et al [18] and Cecchettin and colleagues [17] reported an average net gain of 3.5% and 4.3% in bone mass after a 2 years and 1 year of ipriflavone treatment respectively. In this study we also observed a subtle increase of approximately 1% in the BMD of the spine (L2-4) after 1 year of treatment.…”

Section: Discussionmentioning

confidence: 99%

Ipriflavone for the treatment of osteoporosis

1997

View full text Add to dashboard Cite

“…Segundo Motta (2003), na osteoporose não são encontradas alterações dos níveis séricos de cálcio e fósforo. Estudos realizados por Cecchettin et al (1995) também não encontraram diferenças significativas nos níveis séricos de cálcio ou fósforo durante o tratamento da osteoporose de mulheres na pós-menopausa.…”

Section: Resultsunclassified

“…Mostrou-se que flavonóide foi capaz de induzir aumento de massa óssea após tratamento de 12 meses em mulheres osteoporóticas e efetivo em prevenir perda óssea (Cecchettin et al, 1995).…”

Section: Introductionunclassified

Efeitos de tratamento combinado de alendronato de sódio, atorvastatina cálcica e ipriflavona na osteoporose induzida com dexametasona em ratas

Pinto¹,

Oliveira²,

Carlo³

et al. 2006

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

O objetivo deste trabalho foi estudar a influência das combinações: bifosfonato (alendronato de sódio) + estatina (atorvastatina cálcica), bifosfonato (alendronato de sódio) + flavonóide (ipriflavona) e estatina (atorvastatina cálcica) + flavonóide (ipriflavona) em ratas com osteoporose induzida pelo glicocorticóide dexametasona. As influências das associações dessas substâncias foram pesquisadas pela análise de testes dos marcadores bioquímicos de remodelação óssea, tais como, cálcio e fósforo sérico, fosfatase alcalina óssea e por exames histomorfométricos, caracterizando a densidade trabecular óssea. Através da avaliação da densidade trabecular óssea foi possível verificar o aumento da mesma em todos os tratamentos efetuados. Ressaltando-se, ainda, que as associações contendo alendronato de sódio apresentaram elevadas taxas de restauração tecidual óssea, alcançando valores superiores aos do grupo dos animais normais. Os marcadores bioquímicos não apresentaram resultados estatisticamente significativos, não fornecendo subsídios para o diagnóstico e acompanhamento da osteoporose. No entanto, a avaliação histomorfométrica permitiu a análise estática e dinâmica, bem como detecção de alterações teciduais na unidade metabólica óssea, particularmente, no osso trabecular.

show abstract

“…Ipriflavone is a synthetic isoflavone derivative. The efficacy of ipriflavone in preventing loss of bone mass and in increasing bone mineral content in patients with osteoporosis has been demonstrated in many randomized controlled trials 1–10 . In most of these studies, patients with recent fractures were excluded.…”

Section: Introductionmentioning

confidence: 99%

Effect of ipriflavone on pain due to recent osteoporotic vertebral crush fracture

Rahman

Haq

Chowdhury

2002

APLAR Journal of Rheumatology

View full text Add to dashboard Cite

Aim: Ipriflavone conserves bone mass in postmenopausal osteoporosis. Salmon calcitonin and alendronate, two other anti‐resorptive drugs, have been found to have analgesic effects in osteoporotic acute vertebral fracture. This study aimed to determine if ipriflavone also possesses such an effect. Methods: Thirty‐two women with recent osteoporotic vertebral fractures were randomly assigned to ipriflavone treatment or placebo groups. Ipriflavone was given at the dose of 200 mg three times a day. Non‐steroidal anti‐inflammatory drugs were given ad libitum in both groups. Calcium carbonate (1 g daily) was administered to all subjects. Intensity of pain at rest, on movement and on pressure, pain rating on a 10‐point visual analogue scale, degree of mobility impairment, and supplementary analgesic were assessed at the end of a 3‐month period in both groups to assess the analgesic effect of ipriflavone. Results: Fourteen subjects in the ipriflavone group and 12 in the placebo group completed the trial. After 3 months, all pain variables had decreased significantly in both groups. Intensity of pain at rest and on pressure and supplementary analgesic use were significantly lower in the ipriflavone group compared to the placebo group. Conclusion: The study shows that ipriflavone has an analgesic adjuvant effect in acute osteoporotic vertebral fracture.

show abstract

Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis

Cited by 12 publications

References 9 publications

Ipriflavone for the treatment of osteoporosis

Ipriflavone for the treatment of osteoporosis

Efeitos de tratamento combinado de alendronato de sódio, atorvastatina cálcica e ipriflavona na osteoporose induzida com dexametasona em ratas

Effect of ipriflavone on pain due to recent osteoporotic vertebral crush fracture

Contact Info

Product

Resources

About